All In Biotech

Drug Trial Radar · NCT03970447

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,250

Planned (sponsor's estimate)

Start

Jul 30, 2019

Primary completion

Jun 2028

Study completion Jun 2030

Sponsor

Lead sponsor
Global Coalition for Adaptive ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bayer; Kazia Therapeutics Limited; Kintara Therapeutics, Inc.; Biohaven Pharmaceuticals, Inc.; Vigeo Therapeutics, Inc.; Polaris Group; AstraZeneca; Knoa Pharma
First posted
May 31, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnosed participants. Institutions also enrolling Recurrent participants are marked with an asterisk (\*).

Conditions

  • Glioblastoma

Interventions

  • TemozolomideDrug

    Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg

  • LomustineDrug

    Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg

  • RegorafenibDrug

    Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)

  • RadiationRadiation

    60 Gy

  • PaxalisibDrug

    Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles

  • VAL-083Drug

    Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.

  • VT1021Drug

    Dosage Form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration.

  • TroriluzoleDrug

    Dosage Form: Capsule for oral administration Strength: 100 mg Standard Regimen: Dose as confirmed through the dose finding phase orally BID.

  • ADI-PEG 20Biological

    Dosage Form: Solution for intramuscular injection Strength: 11.5 ± 1.0 mg/ml Standard Regimen: For newly diagnosed patients, 36mg/m2. For recurrent disease patients, dose as confirmed through the dose finding phase intramuscularly once a week

  • AZD1390Drug

    Standard Regimen Newly Diagnosed: Given once daily on days of radiation and once daily for 14 consecutive days after completion of radiation.

  • TinostamustineDrug

    Dosage form: Reconstituted powder for intravenous administration Strength: 2mg/mL Standard Regimen: Dose as confirmed through the dose finding phase, on Day 1 of 21-day cycle for up to 12 cycles in the maintenance phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From date of randomization until the date of death from any cause, or until 12 months following last patient randomization (approximately 2 years), whichever comes first.

Locations

63 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • University of California, San Diego

    La Jolla, California · Recruiting

  • Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California · Active not recruiting

  • University of California, Los Angeles

    Los Angeles, California · Active not recruiting

  • St. Joseph Hospital

    Orange, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Stanford Cancer Center

    Stanford, California · Completed

  • University of Colorado Denver

    Aurora, Colorado · Recruiting

  • Yale Cancer Center / Smilow Cancer Hospital*

    New Haven, Connecticut · Recruiting

  • Mayo Clinic Cancer Center

    Jacksonville, Florida · Completed

  • Sylvester Comprehensive Cancer Center*

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Piedmont Atlanta Hospital

    Atlanta, Georgia · Active not recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Active not recruiting

  • LSU Health Sciences Center - New Orleans

    New Orleans, Louisiana · Completed

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Completed

  • Allina Health Systems/Abbott Northwestern Hospital

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic Cancer Center - Rochester

    Rochester, Minnesota · Completed

  • University of Mississippi Medical Center

    Jackson, Mississippi · Completed

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri · Completed

  • Perlmutter Cancer Center, NYU Langone Health

    New York, New York · Active not recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Active not recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center*

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Active not recruiting

  • Comprehensive Cancer Center of Wake Forest*

    Winston-Salem, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center*

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Ohio State University Cancer Center

    Columbus, Ohio · Active not recruiting

  • University of Pennsylvania - Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania · Active not recruiting

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania · Completed

  • University of Pittsburgh Medical Center - Hillman Cancer Center

    Pittsburgh, Pennsylvania · Active not recruiting

  • Medical University of South Carolina - Hollings Cancer Center

    Charleston, South Carolina · Recruiting

  • Texas Oncology - Austin

    Austin, Texas · Active not recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Active not recruiting

  • University of Texas - MD Anderson Cancer Center

    Houston, Texas · Active not recruiting

  • University of Utah - Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • University of Virginia Health

    Charlottesville, Virginia · Recruiting

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.